KMD Bioscience Unveils Monoclonal Antibody Development Services

TIANJIN, China - Oct. 27, 2023 - PRLog -- Monoclonal antibodies (mAbs) are homogeneous antibodies that originate from a single B cell lineage, ensuring uniform specificity towards a particular epitope on the antigen. The quintessential method for mAbs production is hybridoma technology. In this technique, a mouse is immunized with the target antigen, and subsequent fusion of the isolated B cells with myeloma cells results in hybridoma cells. These hybridomas are then cultured, and the produced mAbs are harvested and purified, ensuring a consistent, high-specificity antibody population.

The general procedure to produce monoclonal antibodies is as follows:
1 Immunization of mice & isolation of splenocytes
2 Preparation of myeloma cells
3 Cell Fusion
4 Clone screening and picking
5 Functional characterization
6 Expansion and purification

About KMD Bioscience

KMD Bioscience has a mature antibody production platform with our well-established antibody engineering technology. At KMD Bioscience, you can gain comprehensive antibody production services including antigen design, peptide synthesis, sequence design, animal immunization, antibody purification, sequecing and antibody labeling.  KMD Bioscience provides monoclonal antibody, polyclonal antibody, recombinant antibody production and development for worldwide customers over 10 years. For more information, Visit us at http://www.kmdbioscience.com/ to have a detailed understanding.

This article serves as a reference material for enthusiasts in scientific research. It does not substitute for professional knowledge or hands on experimental procedures which require more detailed and professional information. In case of any content infringement, kindly reach out to the author for immediate deletion of thecontentious material.